MX2016001383A - Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab. - Google Patents
Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.Info
- Publication number
- MX2016001383A MX2016001383A MX2016001383A MX2016001383A MX2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A
- Authority
- MX
- Mexico
- Prior art keywords
- asthma
- methods
- benralizumab
- exacerbation rates
- reducing exacerbation
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 3
- 229950000321 benralizumab Drugs 0.000 title abstract 2
- 230000005713 exacerbation Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940100602 interleukin-5 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se presentan los métodos para reducir las exacerbaciones de asma en un paciente con asma, que comprenden administrar al paciente una cantidad efectiva del anticuerpo benralizumab que actúa sobre el receptor de interleucina-5 (IL-5R) o un fragmento de unión al antígeno de este.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361864944P | 2013-08-12 | 2013-08-12 | |
PCT/US2014/050080 WO2015023504A1 (en) | 2013-08-12 | 2014-08-07 | Methods for reducing exacerbation rates of asthma using benralizumab |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016001383A true MX2016001383A (es) | 2016-08-03 |
MX368508B MX368508B (es) | 2019-10-07 |
Family
ID=52448837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016001383A MX368508B (es) | 2013-08-12 | 2014-08-07 | Benralizumab para usarse en la reducción de la tasa de exacerbación de asma. |
Country Status (25)
Country | Link |
---|---|
US (2) | US9441037B2 (es) |
EP (1) | EP3033101B1 (es) |
JP (3) | JP6746495B2 (es) |
KR (2) | KR102390714B1 (es) |
CN (2) | CN105451760A (es) |
AU (2) | AU2014306956B2 (es) |
BR (1) | BR112016002401A8 (es) |
CA (1) | CA2918105C (es) |
CY (1) | CY1122132T1 (es) |
DK (1) | DK3033101T3 (es) |
ES (1) | ES2716906T3 (es) |
HK (2) | HK1221644A1 (es) |
HR (1) | HRP20190405T1 (es) |
HU (1) | HUE042607T2 (es) |
LT (1) | LT3033101T (es) |
ME (1) | ME03348B (es) |
MX (1) | MX368508B (es) |
PL (1) | PL3033101T3 (es) |
PT (1) | PT3033101T (es) |
RS (1) | RS58404B1 (es) |
RU (1) | RU2676333C2 (es) |
SG (2) | SG10202005560UA (es) |
SI (1) | SI3033101T1 (es) |
TR (1) | TR201903312T4 (es) |
WO (1) | WO2015023504A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3875487A1 (en) * | 2013-08-12 | 2021-09-08 | Astrazeneca AB | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
KR102337601B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법 |
US20150104447A1 (en) * | 2013-10-15 | 2015-04-16 | Medimmune, Llc | Methods for treating chronic obstructive pulmonary disease using benralizumab |
SI3060229T1 (sl) * | 2013-10-24 | 2021-11-30 | Astrazeneca Ab | Stabilne vodne formulacije protiteles |
RU2019118984A (ru) | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
US10699274B2 (en) | 2015-08-24 | 2020-06-30 | Samsung Electronics Co., Ltd. | Apparatus and method for secure electronic payment |
US10846696B2 (en) | 2015-08-24 | 2020-11-24 | Samsung Electronics Co., Ltd. | Apparatus and method for trusted execution environment based secure payment transactions |
WO2017077391A2 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
US11542316B2 (en) | 2017-01-04 | 2023-01-03 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | S-Arrestin peptides and therapeutic uses thereof |
RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
TW202021983A (zh) * | 2018-09-21 | 2020-06-16 | 美商安納普提斯生物公司 | 用於嗜伊紅性氣喘之抗il-33療法 |
TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
EP1266663A4 (en) | 2000-02-15 | 2003-07-23 | Kyowa Hakko Kogyo Kk | EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2005035583A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Il-5受容体に特異的に結合する抗体組成物 |
US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
JP2010527356A (ja) * | 2007-05-14 | 2010-08-12 | メディミューン,エルエルシー | 好酸球レベルを低下させる方法 |
RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
EP2501228A4 (en) * | 2009-11-18 | 2013-11-13 | Medicinova Inc | TREATMENT OF ACUTE ASTHMA CRISIS AND REDUCTION OF THE PROBABILITY OF HOSPITALIZATION OF PATIENTS WITH SUFFERING |
EP3447491A3 (en) * | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
WO2012158954A1 (en) * | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
US20140328839A1 (en) | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
EP3875487A1 (en) * | 2013-08-12 | 2021-09-08 | Astrazeneca AB | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
KR102337601B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법 |
-
2014
- 2014-08-07 AU AU2014306956A patent/AU2014306956B2/en active Active
- 2014-08-07 CN CN201480043448.XA patent/CN105451760A/zh active Pending
- 2014-08-07 KR KR1020167006559A patent/KR102390714B1/ko active IP Right Grant
- 2014-08-07 PT PT14835826T patent/PT3033101T/pt unknown
- 2014-08-07 LT LTEP14835826.0T patent/LT3033101T/lt unknown
- 2014-08-07 CA CA2918105A patent/CA2918105C/en active Active
- 2014-08-07 SG SG10202005560UA patent/SG10202005560UA/en unknown
- 2014-08-07 EP EP14835826.0A patent/EP3033101B1/en active Active
- 2014-08-07 ES ES14835826T patent/ES2716906T3/es active Active
- 2014-08-07 TR TR2019/03312T patent/TR201903312T4/tr unknown
- 2014-08-07 PL PL14835826T patent/PL3033101T3/pl unknown
- 2014-08-07 US US14/453,942 patent/US9441037B2/en active Active
- 2014-08-07 CN CN202010449434.5A patent/CN111588848A/zh active Pending
- 2014-08-07 HU HUE14835826A patent/HUE042607T2/hu unknown
- 2014-08-07 SG SG11201600481UA patent/SG11201600481UA/en unknown
- 2014-08-07 SI SI201431109T patent/SI3033101T1/sl unknown
- 2014-08-07 RS RS20190305A patent/RS58404B1/sr unknown
- 2014-08-07 WO PCT/US2014/050080 patent/WO2015023504A1/en active Application Filing
- 2014-08-07 RU RU2016108723A patent/RU2676333C2/ru active
- 2014-08-07 JP JP2016534614A patent/JP6746495B2/ja active Active
- 2014-08-07 BR BR112016002401A patent/BR112016002401A8/pt not_active Application Discontinuation
- 2014-08-07 ME MEP-2019-75A patent/ME03348B/me unknown
- 2014-08-07 DK DK14835826.0T patent/DK3033101T3/en active
- 2014-08-07 MX MX2016001383A patent/MX368508B/es active IP Right Grant
- 2014-08-07 KR KR1020227013308A patent/KR20220057637A/ko not_active Application Discontinuation
-
2016
- 2016-08-16 HK HK16109784.3A patent/HK1221644A1/zh unknown
- 2016-09-02 US US15/255,508 patent/US20170198049A1/en not_active Abandoned
- 2016-12-01 HK HK16113684A patent/HK1225302B/zh unknown
-
2019
- 2019-03-01 HR HRP20190405TT patent/HRP20190405T1/hr unknown
- 2019-03-12 CY CY20191100294T patent/CY1122132T1/el unknown
-
2020
- 2020-02-24 AU AU2020201327A patent/AU2020201327A1/en not_active Abandoned
- 2020-04-03 JP JP2020067797A patent/JP2020128375A/ja not_active Withdrawn
-
2022
- 2022-06-07 JP JP2022092216A patent/JP2022120009A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX368508B (es) | Benralizumab para usarse en la reducción de la tasa de exacerbación de asma. | |
AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
TN2012000462A1 (en) | Anti-cd40 antibodies | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX360774B (es) | Antagonistas de progesterona. | |
MX2015013066A (es) | Usos terapéuticos para anticuerpos contra vegfr1. | |
MX368474B (es) | Uso de benralizumab para mejorar síntomas de asma. | |
MX2017014396A (es) | Tratamiento de mieloma multiple. | |
MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. | |
TN2013000265A1 (en) | Anti-cd38 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: ASTRAZENECA AB |
|
FG | Grant or registration |